*Corresponding author,

e-mail : nasrul@unpad.ac.id (N. Wathoni)

https://doi.org/10.24198/idjp.v1i3.23613

Vol 1, Issue 3, 2019 (84-98)

http://journal.unpad.ac.id/idjp

Nanoparticles targeted drug delivery system via epidermal growth factor receptor: a

review

Agus Rusdin

1,6

, Nasrul Wathoni

1,*

, Keiichi Motoyama

, I Made Joni

, Ronny Lesmana

Muchtaridi

1. Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas

Padjadjaran, Sumedang 45363, Indonesia

2. Graduate School of Pharmaceutical Sciences, Kumamoto University, Chuo-ku, Kumamoto 862-0973,

Japan

3. Department of Physics, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran,

Sumedang 45363, Indonesia



Sumedang 45363, Indonesia



Padjadjaran, Sumedang 45363, Indonesia



96128, Indonesia



ABSTRACT

           



therapy. Nanoparticle drug delivery system is a promising multifunctional technique to provide the

           



            

            



such as polymeric nanoparticles, nanometals, and miscellaneous nanoparticles. Most of nanoparticle







Keywords: 

1. Introduction

     



in the family of receptor tyrosine kinases. The



    

     

intercellular tyrosine kinase domain [1-2]. The

      



     



cancer cells progression, formation, metastasis, and



      



       

positive cell, as signalling for several types of cancer,





    

ovarian cancer, head and neck squamous cancers,

      

     

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

consideration for drug targeted in the clinical

treatment of cancer diseases. In previous studies,

     

     

     

     

nanoparticle-targeted drug delivery system

[17-19].

In the last decade, nanoparticle drug delivery

    

approach and the most commonly studied for

the development of diseases treatment. Its



reason for this system to resolve physicochemical







       

     

cancer drugs generally has a poor site selectivity



Therefore, a nanoparticle targeted drug delivery



      

nanoparticle-targeted drug delivery system have



onto gene targeting, enzyme and receptor-like an





       

       

   

resistance, pharmacogenomics, mechanism,

      

      

    

     

     

targeted drug delivery system, related to types

      

mediators.

2. Methodology



      



     

     



2019 as a primary literatures, and 36 journals







Table 1.

Types of

nanoparticle

Name of nanoparticle



nanoparticle

Targeting mediator Targeted cells Ref.

Polymeric

nanoparticle



targeted Chitosan

nanoparticles

  

DDP

[35]

Polymeric

nanoparticle

curcumin-encapsulated and



TPP nanoparticles

Chitosan-TPP   [36]

Polymeric

nanoparticle









  MCF-7 [37]

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

Types of

nanoparticle

Name of nanoparticle



nanoparticle

Targeting mediator Targeted cells Ref.

Polymeric

nanoparticle





DTX and CUR prodrug

nanoparticles

   [38]

Polymeric

nanoparticle



polydopamine Core-shell

Nanoparticle



Polydopamine

  [39]

Polymeric

nanoparticle







 

MCF-7

[40]

Polymeric

nanoparticle





















 



[41]

Polymeric

nanoparticle



nanoparticles

incorporating a ruthenium-



Polylactic-co-

glycolic acid



 



[42]

Metal nanoparticle nanosecond-laser

irradiation - gold

nanoparticles

   [45]

Metal nanoparticle 

nanoparticle

   [46]

Metal nanoparticle 



nanoparticle



lingker



single-domain

ilama-derived anti-





mice

[47]

Metal nanoparticle Multifunctional

nanoclusters of



upconversion

nanoparticle and gold

nanorod

 C-225 







[48]

Metal nanoparticle 2.4 nm thiolate-protected

gold

nanoparticles

  U87 MG,







[49]

Metal nanoparticle 

polydopamine

multifunctional

nanocomposites



polydopamine

  [50]

Metal nanoparticle lipid-encapsulated targeted

superparamagnetic



 

iminothiolane

U-251 [51]

Metal nanoparticle nanoparticles   U-251 [52]

Metal nanoparticle 



nanoparticles



alumnium

 [53]

Table 1. continue

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

3. Discussion

3.1. Nanoparticles drug delivery system

     

essential role in clinical therapy. Multifunctional

     

    



       

surface area is directly proportional to the contact

      

      

dissolution rate [29]. Moreover, nanomedicine in



intermolecular level for curing diseases or repairing

      



polymeric nanoparticle, and magnetic nanoparticles

      

formulated as drug delivery systems [30].

Nanoparticle drug delivery system is a



        

    

drugs[31]. Nanoparticles formulation commonly

used as targeted drug delivery carrier to particular

     

      

      

polymeric, dendrimer, solid lipid nanoparticles,

metal nanoparticles and liposomes. Selection

        

nanoparticles formulation for drug delivery of active

      



     

     

     

     

      

     

Types of

nanoparticle

Name of nanoparticle



nanoparticle

Targeting mediator Targeted cells Ref.

Metal nanoparticle 

nanoparticles

CuS  4T1 cells [54]

Selenium

nanoparticle



selenium nanoparticles

Selenium  



[55]

Selenium

nanoparticle



nanoparticle

Selenium-

gadolinium chelate



DTSSP

NPC cells [56]

Immuno

nanoparticle



immunonanoparticles









thiolated anti-



 [57]

 Smart nanoparticles



molecules

   [58]



nanoparticle

Fluorescent organic

nanoparticles

   [59]

Unimolecular

nanoparticle



dual-sensitive unimolecular

nanoparticles





  [60]



nanoparticle





modifed



 Palmitate-anti-









and SW480



[61]



lipid nanoparticles





nanoparticles



Mal

Pluronic F127  [62]



nanoparticle





   [63]

Table 1. continue

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

nanoparticle formulation also can enhance the

    







   

of drugs in systemic circulation [34].

3.2. EGFR

     

     

      

      

    

    

and an intercellular tyrosine kinase domain [1-2].

    

    



in progression of the cancer cells, cells formation,

metastasis, and angiogenesis [3-5]. Furthermore,

      

       

     

     

        

the primary target for anti-cancer drug delivery



        

     

     

    



    

system [17-19].

3.3. Nanoparticles formulation as an EGFR-

targeted drug delivery system



     

       



        



      

      

      



three years, most of nanoaparticles formulation are

made in nanoparticle targeted drug delivery system

      



impressive thing to learn. Therefore, in this study



nanoparticle formulation (Table 1.)

3.3.1 Polymeric based nanoparticle for EGFR-

targeted drug delivery system



    

     











formulation as a targeted drug delivery system via



Nascimento et al





as a mediator to deliver mad2 

     

     

      



    



after treatment compared to control, more over the



    

      



of the non-targeted nanoparticle system [35].

Using a similar carrier system, chitosan

 et

al       





potential. In vitro     

curcumin-encapsulated folate-conjugated chitosan/



curcumin-encapsulated chitosan/TPP nanoparticles

 

3.4 µM and 12.8 µM in MKN45

line



A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

      



      



  



production





     

  



In another study, Jin et al. created a polymeric

      

 

       

peptide as a targeting mediator. The nanoparticle

     

       

     

    

    

24 hours. Moreover, this system delivered the







      

the impact of delivering curcumin in nanoparticle

      







response and enhanced the delivery of the curcumin



    

       et

al.      





nanoparticle has a mean particle size of 167 nm,



     

curcumin respectively. In targeted drug delivery

      



    

       





    



addition the nanoparticle system has stronger anti-





   et al., performed a polymeric

     

    

     

      

     







      

     





     

     

      

     

negative cell [39].

In other study, formulation of polymeric

     et al., in



of active and passive targeting cancer cells

     

       

     

      

      

   



particle size of 195.3 nm, 0.104 polydispersity

      

      

       

     



     





      

      



     

      

 



[40].

   

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

    et al. for increasing the

    

   

  

  

      

carrier. This study resulted the mean particle size

      



      

    

     

        

       

  



       

dose of 100 nM in 24 and 48 hours. In addition





   

    

       

     



      

the nanoparticle system has a sensitive property





        



       







control

[41].

Gill et al   



111

    



     





system, polylactic-co-glycolic acid used as a

      





      



-4.7 mV zeta potential and 0.236 of polydispersity

       

     

      



     

      

       

     

nanoparticle system. Ru1 uptake and localization

       

after 24 hours treatment. The nanoparticle system

       

     

    



111



     

      

prominent result for uptake of radioactivity into the





tumour muscle ratio range of 2.5-4, in this assay



tumour-associated radioactivity or tumour muscle

      

models [42].

3.3.2 Metal-based nanoparticle for EGFR-targeted

drug delivery system





   

metals have a potential therapy against cancer cells.

Metals also have some special physicochemical

characteristic as supporting mechanism of action,

including magnetic, thermal and photosensitive

       

       

       

      

    

delivery system [43-44].

3.3.2.1 Gold based nanoparticle

Yao et al. developed a metal nanoparticle

using gold as a main metal in nanoparticle

system. This formulation aimed to increase a cell

    

     

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

       





      

results assay proved that the metal nanoparticle



    



       





       

       

      

       

nanoparticle [45].





         





et al. performed a gold nanoparticle formulation,

and studied the changes of secondary structure of

   

investigate the change of secondary structure in



consideration for modifying synthesis procedure



      

       

       

       



        

receptor [46].

In 2018, development of gold nanoparticle

    et al,. The study

      

     





derived as a targeting mediators. In vitro and in

vivo



     



than non-targeted and other nanoparticle systems.

      

      





Cho et al. formulated a multifunctional

nanocluster of NaYF

 



 



up conversion

     



       

       

length of 43 nm, and localized surface plasmonear

800 nm. Results demonstrated that the targeting

      

       

   



    



negative cells

[48].

    

   et al  

       



      

      





     

  





     

     



the selective target delivery

[49].

3.3.2.2 Fe

based nanoparticle



et al



     

    

magnetic resonance imaging and antitumour

   

     



     

This system revealed a high storage capacity of

drug and also has high photo thermal conversion

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

    

      

    

      ∼





     



study demonstrated that the nanoparticles system





     

drug delivery system

[50].



et al

    

lipid encapsulated targeted super paramagnetic iron



    



the system preferentially targeted onto U-251 cells,

       



     





to other cells [51].

 et al. formulated composite magnetic

     

metals. Fe



 

   

     

delivery agent of magneto photothermal therapy

       

      

    

       

       

    

In

vivo



      

study demonstrated that the nanoparticles system

have great potential as a nanoplatform in clinical

treatment for human glioma disease

[52].

3.3.3 ZnO-Aluminium and Cu based nanoparticle

    

       

atoms or compounds as the core system includes

et al. developed a zinc



       

     

  

      



       



    

also proved that the nanoparticles formula could

      

       

     

       

     

lung adenocarcinoma cells

[53].

    

   et al. The nanoparticles system



      



 

infrared-II-responsive photothermal therapy

     

     

     

   

staining demonstrated that the nanoparticles

      

of tumour formation and progression of tumour

vessel. In conclusion, this study suggested that the



the anti-cancer drug for utilized in clinical treatment

for the cancer diseases, and the safety properties of

        

[54].

3.3.4 Selenium-based nanoparticle

     



        

     



A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

    





       





    

   

   

      

     







    



[55].



      

       

       



for magnetic resonance imaging contrast agent,

  







as a drug payload for nasopharyngeal carcinoma

in vitro 

      



      

      

       

property of the nanoparticle system in the tumour

   



[56].

3.3.5 Miscellaneous based nanoparticle for EGFR-

targeted drug delivery system

Kim et al.    

nanoparticles as targeted drug delivery carrier

      

    

       

 



     



      

   

      



      





    

  

     









conventional therapy of cancer diseases

[57].

 et al. designed the smart nanoparticles

      



       

       



       



     

         



tissue through active and passive targeting, the





     

 

uncoated then discharged from endosome via





       

     



cells

[58].



et al







     



      

       



A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

     

   



      



[59].

Chen et al. formulated unimolecular

    

    

  in vitro studies, the optimal condition

        

         

      

materials in unimolecular nanoparticles could

      

positive cancer cells

[60].

Zhang et al   

     

   

       

targeting and enhance the antitumour activity in

colorectal cancer treatment. It consisted of single-

      

    



    

activity in the treatment of colorectal cancer due

in vitro

 in vivo 

      

and short-term cell apoptosis

[61].

Zhai et al   



      

targeting mediator in nanoparticle targeted drug

delivery system for aggressive ovarian cancer cells.

     

      

to in vitro       

     

    



     



       



this study suggested that nanoparticles system have

   



[62].

       







      

     

     

     

      

PC9R and PC9 cells. Zhou et al also found that in



 

apoptosis markedly increased. Through this study, a





[63].

4. Conclusion



of several cancer cells due to its essential role in



primary target in cancer diseases treatment.

   



to mediate this targeted therapy. Nanoparticles

systems such as nano-polymeric, nanometal, and

    



       

       

underlying mechanism of targeted drug delivery

system is the result of conjugation of targeting





      

promising anti-cancer drugs carrier on clinical





5. Acknowledgement

      





      

this study.

References

[1] 

   Nat. Rev. Mol.

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

cell Biol.22001

[2]        

     



chromosome 7. Cytogenet. Genome Res.35,

1983

[3] Suzuki, S. et al.   



receptor in nonsmall cell lung carcinomas: an



Cancer Interdiscip. Int. J.

Am. Cancer Soc.1032005

[4]   et al.  

    

in human tumours: implications for

antiangiogenic tumour therapies. Cancer

Res.602000

[5]      

     

    

  N. Engl. J. Med.364, 947–955

2011

[6] Wang, J. et al.    

kinase domain duplication to targeted

Int. J. cancer144, 2677–

2019

[7]    et al.  

    

therapy in head and neck squamous cell cancer

models. J. Nucl. Med.602019

[8] Ye, M. et al.    

   



  J. Cancer10, 757

2019

[9]        

      

anti‑    

miR‑    

Oncol. Lett.162018

[10] 

      

     

    

    

Oncogenesis72018

[11]     et al.  





head and neck squamous cell carcinoma.

Front. Oncol.82018

[12]   et al.  

    

in locoregionally advanced nasopharyngeal

 

BMC Cancer182018

[13] Railkar, R. et al.  

  



    Mol.

Cancer Ther.162017

[14]   et al.   

sequencing in Chinese colorectal cancer

    

facilitated precision cancer medicine.

Oncotarget82017

[15]   

        





    

therapy. Mol. Cancer Res.102012

[16] 

     



resistance of ovarian cancer cells to targeted

  Int. J. Mol.

Sci.132012

[17] Ninomiya, T. et al.

     

    

    

Clin.

Lung Cancer202019

[18] et al.

   

for parenteral administration of hydrophilic

macromolecular drugs: synthesis, preparation

     Int. J.

Pharm.5112016

[19]        



nano-scale delivery system for the molecular

Int. J.

Radiat. Biol.922016

[20] 

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

Nanoparticle delivery of cancer drugs. Annu.

Rev. Med.632012

[21]        

    Exp. Mol.

Pathol.862009

[22]  

of nanoparticle systems in drug delivery

technology. Saudi Pharm. J.262018

[23] Kamei, K. et al. Integrated heart/cancer on

        

cancer drugs in vitro. RSC Adv.7, 36777–

2017

[24]    et al. Mechanisms of



Expert Opin. Ther. Targets13, 339–362

2009

[25]      

      

anti-egfr drugs and other molecular targeted

agents as anti-cancer strategy. Curr. Cancer

Ther. Rev.32007

[26]      

     

acquired resistance to anti‑ 

drugs in cancer therapy. Dierentiation75,

2007

[27]         





drug scheduling and patient selection.

Pharmacol. Ther.1542015

[28]     





factor for targeted therapies in non-small cell

lung cancer—is there a „golden standard” in

diagnostics? Adv. Respir. Med.82, 311–322

2014

[29]        

Nanoparticulate drug delivery systems. 166,



[30]     



drug delivery systems. Pharmacol. Reports64,

2012

[31]      

NATURE-LONDON-1998

[32]       

     

in mice after oral administration. Carbohydr.

Polym.712008

[33] Yan, C. et al.  

  

   



 AAPS PharmSciTech20, 30

2019

[34] Pi, J. et al.



 Asian J. Pharm. Sci.14, 154–164

2019

[35] et al.





 

Acta Biomater.472017

[36]         

   

  

nanoparticles. Int. J. Nanomedicine13, 903

2018

[37]   et al.  

nanoparticles as a curcumin delivery system

Nanoscale9, 16365–

2017

[38] Yan, J. et al.   

and curcumin prodrug via dual-targeted

   

activity against prostate cancer. Biomed.

Pharmacother.882017

[39] 



core-shell nanoparticle for light induced cancer

thermochemotherapy. Acta Biomater.59, 181–

2017

[40] Clemons, T. D. et al.  



    

Langmuir342018

[41] Cui, X. et al.  

    

    

  

ACS

Appl. Mater. Interfaces102018

[42] Gill, M. R. et al.   

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

nanoparticles incorporating a ruthenium-

   

    

cells. Nanoscale102018

[43]        



from drug design perspective. Drug Des.

Devel. Ther.112017

[44] 



nanotool against cancer. Drug Discov.

Today202015

[45] 

     

    

   

irradiation. Int. J. Nanomedicine12, 5659

2017

[46]    et al. FTIR study of

    

    

conjugation. Biochim. Biophys. Acta (BBA)-

General Subj.18622018

[47]          

        

    

gold nanoparticle CT imaging of lung cancer.

PLoS One132018

[48] Cho, S. K. et al. Multifunctional nanoclusters

    

nanoparticle and gold nanorod for simultaneous



cancer. Mater. Sci. Eng. C972019

[49] et al.

evaluation of 2.4 nm thiolate-protected gold

    

     

Nanotechnology302019

[50] Mu, X. et al.   

  

multifunctional nanocomposites for MRI and

antitumour chemo-photothermal therapy. Int.

J. Nanomedicine122017

[51] et al.

   

using lipid-encapsulated targeted

   

in vitro. J. Nanobiotechnology152017

[52] et al.

    

targeted magneto-photothermal therapy of

glioma cells. Int. J. Nanomedicine13, 2491

2018

[53]      

      



are sensitive to non-autophagic cell death



   J. Toxicol. Sci.42,

2017

[54]          

   

integrating near-infrared-II-responsive

photothermal therapy and anti-vessel

treatment. Int. J. Nanomedicine13, 7289

2018

[55] Pi, J. et al.

    

delivery to achieve enhanced anticancer



   

Drug Deliv.242017

[56] et al.



and Tumour Microenvironment Responsive

    

Therapy of Nasopharyngeal Carcinoma. ACS

Appl. Mater. Interfaces2019

[57] Kim, J. S. et al.  

    

immunonanoparticles. Int. J. Nanomedicine13,

2018

[58] et al.





targeting. Nanomedicine Nanotechnology,

Biol. Med.152019

[59]   et al.  

   

   Nanoscale9,

2017

[60]         

  

   

J. Control. Release259, 105–

2017

A. Rusdin et al / Indo J Pharm 3 (2019) 84-98

[61] Zhang, Z. et al.

   

     



cancer treatment. Int. J. Nanomedicine13,

2018

[62] Zhai, J. et al.  

    

drug delivery systems for the treatment of

aggressive ovarian cancer. ACS Appl. Mater.

Interfaces102018

[63] Zhou, J. et al.   

  

Cell. Physiol. Biochem.47,

2018